Persistent Asset Partners’s Definium Therapeutics DFTX Stock Holding History

Persistent Asset Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$648K	Sell	13,778 -2,083	-13%	-$51.5K	0.19%	90
2026 Q1	$300K	Buy	+15,861	New	+$269K	0.11%	155
2025 Q4	–	Sell	-24,282	Closed	-$286K	–	411
2025 Q3	$286K	Sell	24,282 -12,360	-34%	-$115K	0.2%	113
2025 Q2	$238K	Buy	+36,642	New	+$241K	0.18%	106

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Persistent Asset Partners's DFTX Position: Q2 2026 in Review

Persistent Asset Partners reduced its Definium Therapeutics (DFTX) stake by 13% in Q2 2026, selling an estimated $51.5K and leaving 13,778 shares worth $648K. The position accounts for 0.19% of the portfolio, ranked #90.

Persistent Asset Partners first reported a position in DFTX in Q2 2025 and has held it in 4 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Persistent Asset Partners held 13,778 shares of Definium Therapeutics worth $648K as of Q2 2026.
Persistent Asset Partners sold 2,083 Definium Therapeutics shares in Q2 2026, an estimated $51.5K.
Definium Therapeutics made up 0.19% of Persistent Asset Partners's portfolio in Q2 2026, its #90 holding.
Persistent Asset Partners first reported a position in Definium Therapeutics in Q2 2025 and has held it in 4 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.